Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex
-
Published:2023-06-23
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Sun YilunORCID, Baechler Simone A., Zhang Xiaohu, Kumar Suresh, Factor Valentina M., Arakawa Yasuhiro, Chau Cindy H.ORCID, Okamoto Kanako, Parikh Anup, Walker BobORCID, Su Yijun P., Chen JijiORCID, Ting Tabitha, Huang Shar-yin N., Beck Erin, Itkin Zina, McKnight Crystal, Xie ChangqingORCID, Roper Nitin, Nijhawan Deepak, Figg William Douglas, Meltzer Paul S.ORCID, Yang James C.ORCID, Thomas Craig J.ORCID, Pommier YvesORCID
Abstract
AbstractColorectal cancers (CRCs) are prevalent worldwide, yet current treatments remain inadequate. Using chemical genetic screens, we identify that co-inhibition of topoisomerase I (TOP1) and NEDD8 is synergistically cytotoxic in human CRC cells. Combination of the TOP1 inhibitor irinotecan or its bioactive metabolite SN38 with the NEDD8-activating enzyme inhibitor pevonedistat exhibits synergy in CRC patient-derived organoids and xenografts. Mechanistically, we show that pevonedistat blocks the ubiquitin/proteasome-dependent repair of TOP1 DNA-protein crosslinks (TOP1-DPCs) induced by TOP1 inhibitors and that the CUL4-RBX1 complex (CRL4) is a prominent ubiquitin ligase acting on TOP1-DPCs for proteasomal degradation upon auto-NEDD8 modification during replication. We identify DCAF13, a DDB1 and Cullin Associated Factor, as the receptor of TOP1-DPCs for CRL4. Our study not only uncovers a replication-coupled ubiquitin-proteasome pathway for the repair of TOP1-DPCs but also provides molecular and translational rationale for combining TOP1 inhibitors and pevonedistat for CRC and other types of cancers.
Funder
U.S. Department of Health & Human Services | National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference71 articles.
1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021). 2. Fuchs, C., Mitchell, E. P. & Hoff, P. M. Irinotecan in the treatment of colorectal cancer. Cancer Treat. Rev. 32, 491–503 (2006). 3. Vogel, A., Hofheinz, R. D., Kubicka, S. & Arnold, D. Treatment decisions in metastatic colorectal cancer—beyond first and second line combination therapies. Cancer Treat. Rev. 59, 54–60 (2017). 4. Thomas, A. & Pommier, Y. Targeting topoisomerase I in the era of precision medicine. Clin. Cancer Res. 25, 6581–6589 (2019). 5. Pommier, Y., Sun, Y., Huang, S. N. & Nitiss, J. L. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell Biol. 17, 703–721 (2016).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|